Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced the launch of an AI-powered R&D platform focused on the proteolysis targeting chimera (PROTAC) mechanism, designed to accelerate rational design and clinical translation of PROTAC lead compounds. The platform addresses the 80% of disease-associated human proteins currently considered “undruggable” by traditional small-molecule approaches.
Platform Launch
Item
Detail
Company
Sunshine Lake Pharma Co., Ltd. (HKEX: 6887)
Platform Name
PROTAC Intelligent R&D Platform
Technology Focus
AI-driven PROTAC molecule design
Core Database
HEC-PROTAC DB (high-quality, structured PROTAC-specific database)
Launch Date
8 Jan 2026
Key Innovation
Systematic integration of molecular structures, degradation activity, physicochemical properties, and PK parameters
Technology Profile
PROTAC Mechanism: Leverages cellular ubiquitin-proteasome system to induce targeted protein degradation, offering catalytic action, resistance-overcoming potential, and lower toxicity vs. traditional inhibitors
Market Gap:~80% of disease-associated proteins lack suitable binding pockets, making them inaccessible to conventional small molecules
Fragmented experimental data across patents, literature, and clinical pipelines
Lack of unified standards hinders AI model training
Development remains heavily reliant on empirical trial-and-error
AI Solution: Sunshine’s platform applies generative AI and graph neural networks to predict optimal PROTAC architectures, reducing design cycles by an estimated 60‑70%
Database & AI Integration
Data Module
Content
Molecular Structures
>50,000 PROTAC molecules from patents, literature, and clinical pipelines
Degradation Activity
DC₅₀, D_max, t½ degradation kinetics across 200+ targets
HEC-PROTAC DB enables quantitative structure-degradation relationship (QSDR) modeling
AI workflows generate Linker libraries optimized for ternary complex geometry, E3 ligand efficiency, and drug-like properties simultaneously
Market Context & Competitive Landscape
Parameter
2026E
2027E
2028E
Global PROTAC Market
$1.8 billion
$3.2 billion
$5.5 billion
AI-Driven PROTAC Share
5 %
12 %
25 %
Sunshine Platform Value
¥500 million
¥1.2 billion
¥2.8 billion
Pipeline Candidates (est.)
3 programs
6 programs
10 programs
Competitive Landscape:
Arvinas (US) and C4 Therapeutics (US) lead clinical-stage PROTACs (ARV-471, CFT8919) but rely on traditional med-chem
Kymera (US) focuses on IRAK4/STAT3 with AI assistance but lacks integrated platform
Insilico Medicine (HK) uses AI for degrader design but no dedicated PROTAC database
Sunshine’s Differentiation:First China-based AI-PROTAC platform with proprietary structured database; modular AI enables multi-parameter optimization vs. single-target focus
Strategic Positioning
Pipeline Acceleration: Platform targets oncology (undruggable transcription factors) and autoimmune (kinase degraders) indications; first IND filing expected 2027
Partnership Potential: Sunshine in discussions with MNCs for platform licensing (estimated $50‑80 million upfront per target) and co-development deals
Technology Moat:HEC-PROTAC DB is closed-loop (internal data continuously fed back into AI models), creating self-reinforcing accuracy improvements
Financial Impact: Platform expected to reduce R&D costs by ¥200 million/year and shorten preclinical timelines from 48 months to 18 months
Forward‑Looking Statements This brief contains forward‑looking statements regarding Sunshine Lake Pharma’s AI platform capabilities, pipeline advancement, and market positioning. Actual results may differ due to AI model accuracy, target tractability, competitive dynamics, and regulatory acceptance of AI-designed molecules.-Fineline Info & Tech
By Fineline Cube 